Genmab A/S
CSE:GMAB
Genmab A/S
Change in Working Capital
Genmab A/S
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genmab A/S
CSE:GMAB
|
Change in Working Capital
-kr359.3m
|
CAGR 3-Years
43%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-2%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Change in Working Capital
kr98.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Change in Working Capital
-€65.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-27%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Change in Working Capital
-kr957.1m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Change in Working Capital
kr4m
|
CAGR 3-Years
60%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
9%
|
|
|
Saniona AB
STO:SANION
|
Change in Working Capital
-kr13.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
What is Genmab A/S's Change in Working Capital?
Change in Working Capital
-359.3m
DKK
Based on the financial report for Mar 31, 2025, Genmab A/S's Change in Working Capital amounts to -359.3m DKK.
What is Genmab A/S's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
-2%
Over the last year, the Change in Working Capital growth was 66%. The average annual Change in Working Capital growth rates for Genmab A/S have been 43% over the past three years , -16% over the past five years , and -2% over the past ten years .
You don't have any saved screeners yet